Loading...

Loading...

Adjust height of sidebar

KMap

People

Adjust height of sidebar

KMap

Profile

Picture of Josef Vagner

Josef Vagner

Director, Ligand Discovery Laboratory | Research Associate Professor, Pharmacology | Research Professor | Member of the Graduate Faculty

Collaboration(39)

Todd Vanderah
Russell Witte
William Montfort
Ronald Lynch
Scott Boitano

Page 1 of 8

Grants(26)

A Role for Pharmaceutical Control of Protease-activated Receptor-2 for the Treatment of Asthma
Active·2024·$71.7K / $716.7K·
External
Co-Investigator (COI)
pharmaceutical control, protease-activated receptor-2, asthma treatment, role of protease, drug therapy
Defining Mechanisms Of Cc16 On Epithelial-driven Host Responses To Pathogens
Active·2024·$30.3K / $606.4K·
External
Co-Investigator (COI)
lung inflammation, host-pathogen interaction, epithelial cells, immune response, biomarker
Development of Small Molecule Antagonists of PAR2 for Oral Treatment of Asthma
Active·2023·$57.9K / $154.4K·
External
Co-Investigator (COI)
asthma, drug development, small molecule, oral treatment
Development of a Novel Therapy to Treat COPD
Active·2023·$280K / $100K·
External
Co-Investigator (COI)
therapeutic intervention, respiratory medicine, drug development, chronic disease management, biomedical innovation
Development of SP-A-Derived Peptidomimetics for the Treatment of Asthma - Phase II
Active·2022·$510.6K / $1M·
External
Co-Investigator (COI)
peptidomimetics, asthma, sp-a-derived, treatment, development

Page 1 of 6

Publications(40)

Recent

Beta-arrestin-biased protease-activated receptor-2 antagonists preferentially limit allergen-induced responses in vivo.

2023

g-protein signaling, allergic response, drug development, protease-activated receptor-2, biased agonism

A humanized protease-activated receptor-2 mouse as a model for allergic asthma

2023

mouse models, allergic asthma, protease-activated receptor-2, humanized model, immune response

PAR2 activation in the dura causes acute behavioral responses and priming to glyceryl trinitrate in a mouse migraine model

2023

pain, neuroscience, migraine, inflammation, pharmacology

C781, a beta;Arrestin Biased Antagonist at Protease-Activated Receptor-2 PAR2) Displays in vivo Efficacy Against Protease-Induced Pain in Mice

2023

pain, drug development, protease-activated receptor-2 (par2), in vivo efficacy, mice

Protease-Activated Receptor 2 PAR2) expressed in sensory neurons contributes to signs of pain and neuropathy in paclitaxel treated mice

2023

neuropathic pain, sensory neurons, protease-activated receptor-2, paclitaxel, mouse model

Alternaria Alternata-induced airway epithelial signaling and inflammatory responses via protease-activated receptor-2 expression

2022

airway inflammation, protease-activated receptors, epithelial signaling, fungal-induced inflammation, respiratory allergy

A Role for Protease Activated Receptor Type 3 PAR3) in Nociception Demonstrated Through Development of a Novel Peptide Agonist

2021

pain, neuroscience, peptide, receptor, drug development

Novel lipidated agonists and antagonists to protease-activated receptor 2 PAR2)

2021

lipidated compounds, protease-activated receptor-2, agonists, antagonists, novel compounds

Alternaria alternata-induced airway epithelial signaling and inflammatory responses via protease-activated receptor-2 expression.

2021

airway inflammation, epithelial signaling, protease-activated receptor-2, allergic response, fungal-induced inflammation

Beta-arrestin-biased proteinase-activated receptor-2 antagonist C781 limits allergen-induced acute asthma response

2021

biased signaling, asthma, proteinase-activated receptor-2, allergen, antagonist